When Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen dialed into a Teams video call with Chairman Helge ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

The company pointed to "recent market challenges" and "share price decline" as reasons for Lars Fruergaard Jørgensen's ...

Novo Nordisk has announced that chief executive Lars Fruergaard Jørgensen will step down just days after the pioneering maker of obesity drugs cut its profit forecast. The Danish group said on Friday ...

The CEO of Danish pharmaceutical giant Novo Nordisk, known for its blockbuster weight-loss drug Ozempic, will step down, the ...

Lars Fruergaard Jørgensen is stepping down as Novo Nordisk CEO, with the company citing its stock's recent struggles.

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...